Lazard Asset Management
PBYI icon

Lazard Asset Management’s Puma Biotechnology PBYI Stock Holding History

Lazard Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Sell
17,970
-41,605
-70% -$268K ﹤0.01% 1711
2025
Q4 		$354K Sell
59,575
-3,572
-6% -$19K ﹤0.01% 1480
2025
Q3 		$335K Buy
+63,147
New +$268K ﹤0.01% 1469
2025
Q2 		– Sell
-2,100
Closed -$6K – 2474
2025
Q1 		$6K Sell
2,100
-395
-16% -$1.24K ﹤0.01% 2176
2024
Q4 		$7K Buy
2,495
+2,005
+409% +$5.83K ﹤0.01% 2118
2024
Q3 		$1K Sell
490
-107,413
-100% -$325K ﹤0.01% 2189
2024
Q2 		$351K Buy
107,903
+58,437
+118% +$257K ﹤0.01% 1347
2024
Q1 		$262K Buy
49,466
+48,520
+5,129% +$261K ﹤0.01% 1217
2023
Q4 		$4K Buy
+946
New +$3.13K ﹤0.01% 2132
2021
Q3 		– Sell
-6,984
Closed -$64K – 2254
2021
Q2 		$64K Buy
+6,984
New +$70.8K ﹤0.01% 1501

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Lazard Asset Management's PBYI Position: Q1 2026 in Review

Lazard Asset Management reduced its Puma Biotechnology (PBYI) stake by 70% in Q1 2026, selling an estimated $268K and leaving 17,970 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Lazard Asset Management first reported a position in PBYI in Q2 2021 and has held it in 10 quarters since. The position peaked at $354K in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Lazard Asset Management held 17,970 shares of Puma Biotechnology worth $115K as of Q1 2026.
  • Lazard Asset Management sold 41,605 Puma Biotechnology shares in Q1 2026, an estimated $268K.
  • Puma Biotechnology made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1711 holding.
  • Lazard Asset Management first reported a position in Puma Biotechnology in Q2 2021 and has held it in 10 quarters since.
  • Lazard Asset Management's Puma Biotechnology position peaked at $354K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.